Loading...

PE anti-human HLA-A,B,C Antibody

Pricing & Availability
Clone
W6/32 (See other available formats)
Regulatory Status
RUO
Other Names
Major Histocompatibility Class I, MHC class I
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
W632_PE_072607
Human peripheral blood lymphocytes stained with W6/32 PE
  • W632_PE_072607
    Human peripheral blood lymphocytes stained with W6/32 PE
See PE spectral data
Cat # Size Price Save
311405 25 tests ¥21,560
311406 100 tests ¥47,520
Description

MHC class I antigens associated with β2-microglobulin are expressed by all human nucleated cells. MHC class I molecules are involved in presentation of antigens to CD8+ T cells. They play an important role in cell-mediated immune responses and tumor surveillance.

Product Details
Technical data sheet

Product Details

Reactivity
Human,Cynomolgus,Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone W6/32 recognizes residues in the N terminus of the human ß2-microglobulin molecule21.

Additional reported applications (for the relevant formats) include: immunoprecipitaton2, Western blotting (non-reducing)3, immunohistochemical staining of acetone-fixed frozen tissue sections4,5, blocking6,7, inhibition of NK cell-mediated lysis10, and activation8,9. Clone W6/32 has been reported not to be suitable for immunohistochemistry on paraffin sections17. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays. For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 311428) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Darrow TL, et al. 1989. J. Immunol. 142:3329.
  2. Stern P, et al. 1987. J. Immunol. 138:1088.
  3. Tran TM, et al. 2001. Immunogenetics 53:440.
  4. Barbatis C, et al. 1981. Gut 22:985.
  5. Ayyoub M, et al. 2004. Cancer Immunity 4:7.
  6. DeFelice M, et al. 1990. Cell. Immunol. 126:420.
  7. Fayen J, et al. 1998. Int. Immunol. 10:1347.
  8. Turco MC, et al. 1988. J. Immunol. 141:2275.
  9. Geppert TD, et al. 1989. J. Immunol. 142:3763.
  10. Wooden SL, et al. 2005. J. Immunol. 175:1383.
  11. Nagano M, et al. 2007. Blood 110:151.
  12. McLoughlin RM,et al.2008. J. Immunol. 181:1323. PubMed
  13. Takahara M, et al.2008. J. Leukoc. Biol. 83:742. PubMed
  14. Lunemann A, et al.2008. J. Immunol. 181:6170. PubMed
  15. Laing BJ, et al. 2010. J. Thorac Cardiovasc Surg. 139:1402. PubMed
  16. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  17. Vambutas A, et al. 2000. Clin. Diagn. Lab. Immun. 7:79.
  18. Coppieters KT, et al. 2012. J. Exp. Med. 209:51. (epitope)
  19. Crivello P, et al. 2013. Hum Immunol. 22:100. PubMed
  20. Jung Y, et al. 2015. Mol Cancer Res. 13:197. PubMed
  21. Shields MJ. Ribaudo RK. 1998. Tissue Antigens. 51(5):567-70. (epitope)
Product Citations
  1. Wang B, et al. 2017. Stem Cell Res Ther.. 10.1186/s13287-017-0744-6. PubMed
  2. Mitchell K, et al. 2018. J Exp Med. 215:1709. PubMed
  3. Martufi M, et al. 2019. CRISPR J. 2:31. PubMed
  4. Oshchepkova A, et al. 2019. Micromachines (Basel). 0.9375. PubMed
  5. Miller MS, et al. 2019. J Biol Chem. 294:19322. PubMed
  6. Iraqi M, et al. 2020. Front Cell Infect Microbiol. 10:48. PubMed
  7. Javitt A, et al. 2019. Front Immunol. 10:141. PubMed
  8. Leite NC, et al. 2020. Cell Reports. 32(2):107894.. PubMed
  9. Poznanski SM, et al. 2018. Cancer Immunol Res. 1.065277778. PubMed
  10. Merlo A, et al. 2010. J Immunol. 184:5895. PubMed
  11. Hu W, et al. 2012. Asian J Androl. 14:695. PubMed
  12. Meissner T, et al. 2012. Biochem Biophys Res Commun. 418:786. PubMed
  13. Vantourout P, et al. 2014. Sci Transl Med. 6:231. PubMed
  14. Grossmann N, et al. 2014. Nat Commun. 5:5419. PubMed
  15. Skora A, et al. 2015. Proc Natl Acad Sci U S A. 112: 9967-9972. PubMed
  16. Blees A, et al. 2015. Sci Rep. 5:17341. PubMed
  17. Salzberger W, et al. 2015. PLoS One. 10: 0145324. PubMed
  18. Herbring V, et al. 2016. Sci Rep. 6:36907. PubMed
  19. Nazari-Shafti TZ, et al. 2020. Biomolecules. 10:00. PubMed
  20. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  21. Portillo AL, et al. 2021. iScience. 24(6):102619. PubMed
  22. Kenty JH, et al. 2021. STAR Protocols. 2(3):100675. PubMed
  23. Singh MV, et al. 2020. J Leukoc Biol. 109:807. PubMed
  24. Strijker JGM, et al. 2021. J Pers Med. 11:. PubMed
  25. Chida K, et al. 2021. Biol Pharm Bull. 44:1551. PubMed
  26. Chen R, et al. 2021. Front Oncol. 11:743050. PubMed
  27. Liang YH, et al. 2021. J Biomed Sci. 28:75. PubMed
  28. Brohl AS, et al. 2021. Cell Rep. 37:110047. PubMed
  29. Izumi K, et al. 2021. Immunohorizons. 5:687. PubMed
  30. Feola S, et al. 2021. ACS Nano. 15:15992. PubMed
  31. Song C, et al. 2022. Stem Cell Res Ther. 13:48. PubMed
  32. Taniguchi H, et al. 2022. Cell Rep. 39:110814. PubMed
  33. Arakawa A, et al. 2021. J Immunol. 207:2235. PubMed
  34. Saluzzo S, et al. 2022. STAR Protoc. 3:101470. PubMed
  35. Lee PC, et al. 2022. J Clin Invest. 132:. PubMed
  36. Palmer CD, et al. 2022. Nat Med. 28:1619. PubMed
  37. Blank A, et al. 2021. J Pathol. 253:160. PubMed
  38. Minervina AA, et al. 2022. Nat Immunol. 23:781. PubMed
  39. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  40. Zhang J, et al. 2022. Int J Mol Sci. 23:. PubMed
  41. Gerace D, et al. 2023. Cell Rep Med. 4:100879. PubMed
  42. Meyer S, et al. 2023. Cell Rep. 42:111995. PubMed
  43. Vidard L, et al. 2023. Immun Inflamm Dis. 11:e749. PubMed
  44. Shen JZ, et al. 2022. Mol Cell. 82:1123. PubMed
  45. Hiatt JB, et al. 2022. Clin Cancer Res. 28:4551. PubMed
  46. Zhang X, et al. 2022. Cell Rep. 40:111363. PubMed
  47. Chimienti R, et al. 2022. Cell Rep. 40:111423. PubMed
  48. Fox DB, et al. 2023. NPJ Precis Oncol. 7:25. PubMed
RRID
AB_314874 (BioLegend Cat. No. 311405)
AB_314875 (BioLegend Cat. No. 311406)

Antigen Details

Structure
Ig superfamily
Distribution

All nucleated cells

Function
Antigen presentation
Ligand/Receptor
CD3/TCR, CD8
Biology Area
Immunology, Innate Immunity
Molecular Family
MHC Antigens
Antigen References

1. Barclay AN, et al. Eds. 1993. The Leukocyte Antigen FactsBook. Academic Press Inc. San Diego.

Gene ID
3105 View all products for this Gene ID
UniProt
View information about HLA-A on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 3    Revision Date: 11/20/2014

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account